Full Press Release Details
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.
ALLO
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Key Takeaway: Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma